Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4

Hepatology Communications

Volumn 2, Issue 11, 2018, Pages 1311-1319

  Leung, Daniel H ^a   Wirth, Stefan ^b   Yao, Betty B ^c   Viani, Rolando M ^c,m   Gonzalez Peralta, Regino P ^d,n   Jonas, Maureen M ^e   Lobritto, Steven J ^f   Narkewicz, Michael R ^g   Sokal, Etienne ^h   Fortuny, Clàudia ⁱ   Hsu, Evelyn K ^j   Del Valle Segarra, Antonio ^k   Zha, Jiuhong ^c   Larsen, Lois ^c   Liu, Li ^c   Shuster, Diana L ^c,o   Cohen, Daniel E ^c   Rosenthal, Philip ^l  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WITTEN HERDECKE   (Germany)

^c ABBVIE INC   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f NewYork Presbyterian Hospital   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^k San Jorge Children's Hospital   (Puerto Rico)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ FLORIDA HOSPITAL   (United States)

^o PRA HEALTH SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DASABUVIR; INTERFERON; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CAUCASIAN; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS SUBTYPE 1A; HEPATITIS C VIRUS SUBTYPE 1B; HUMAN; LIMIT OF QUANTITATION; LIVER CIRRHOSIS; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OPEN STUDY; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RHINOPHARYNGITIS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

EID: 85065098371     PISSN: None     EISSN: 2471254X     Source Type: Journal    
DOI: 10.1002/hep4.1250     Document Type: Article

References (29)

1. AASLD-IDSA. HCV guidance: recommendations for testing, managing, and treating hepatitis C. https://www.hcvguidelines.org. Accessed June 21, 2018.
2. European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018;69:461-511.
3. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-176.
4. WHO. Global hepatitis report 2017. Published 2017. https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/. Accessed June 21, 2018.
5. CDA Foundation. 52 million children suffering from hepatitis. https://cdafound.org/featured3/. Published January 5, 2018. Accessed June 21, 2018.
6. Delgado-Borrego A, Smith L, Jonas MM, Hall CA, Negre B, Jordan SH, et al. Expected and actual case ascertainment and treatment rates for children infected with hepatitis C in Florida and the United States: epidemiologic evidence from statewide and nationwide surveys. J Pediatr 2012;161:915-921.
7. Bortolotti F, Verucchi G, Camma C, Cabibbo G, Zancan L, Indolfi G, et al. Italian Observatory for HCV Infection and Hepatitis C in Children. Long-term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008;134:1900-1907.
8. Garcia-Monzon C, Jara P, Fernandez-Bermejo M, Hierro L, Frauca E, Camarena C, et al. Chronic hepatitis C in children: a clinical and immunohistochemical comparative study with adult patients. Hepatology 1998;28:1696-1701.
9. Barshes NR, Udell IW, Lee TC, O'Mahony CA, Karpen SJ, Carter BA, et al. The natural history of hepatitis C virus in pediatric liver transplant recipients. Liver Transpl 2006;12:1119-1123.
10. Goodman ZD, Makhlouf HR, Liu L, Balistreri W, Gonzalez-Peralta RP, Haber B, et al. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology 2008;47:836-843.
11. Genentech, Inc. PEGASYS (peginterferon alfa-2a). US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf. Published 2011. Accessed June 21, 2018.
12. Ghany MG, Strader DB, Thomas DL. Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-1374.
13. Indolfi G, Hierro L, Dezsofi A, Jahnel J, Debray D, Hadzic N, et al. Treatment of chronic hepatitis C virus infection in children: a position paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:505-515.
14. AbbVie Inc. VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/206619s017lbl.pdf. Published March 2017. Accessed June 21, 2018.
15. AbbVie Inc. VIEKIRAX (ombitasvir, paritaprevir, and ritonavir tablets) Summary of product characteristics. Available at: https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003839/WC500183997.pdf. Accessed June 21, 2018.
16. AbbVie Inc. EXVIERA (dasabuvir tablets). Summary of product characteristics https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003837/WC500182233.pdf. Accessed June 21, 2018.
17. AbbVie Inc. TECHNIVIE (ombitasvir, paritaprevir, and ritonavir tablets) US prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207931s011lbl.pdf. Published March 2017. Accessed June 21, 2018.
18. Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014;147(359–365):e351.
19. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1594-1603.
20. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370:1983-1992.
21. Hezode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015;385:2502-2509.
22. Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370:1973-1982.
23. Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourliere M, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370:1604-1614.
24. Ganne-Carrie N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, et al. Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006;44:1511-1517.
25. Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis 2013;56:961-967.
26. Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin CH, Kersey K, et al. The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12–17 years old with hepatitis C virus genotype 1 infection. Hepatology 2017;66:371-378.
27. Wirth S, Rosenthal P, Gonzalez-Peralta RP, Jonas MM, Balistreri WF, Lin CH, et al. Sofosbuvir and ribavirin in adolescents 12–17 years old with hepatitis C virus genotype 2 or 3 infection. Hepatology 2017;66:1102-1110.
28. Yakoot M, El-Shabrawi MH, AbdElgawad MM, Mahfouz AA, Helmy S, Abdo AM, et al. Dual sofosbuvir/daclatasvir therapy in adolescent patients with chronic hepatitis C infection. J Pediatr Gastroenterol Nutr 2018;67:86-89.
29. Lalezari J, Sullivan JG, Varunok P, Galen E, Kowdley KV, Rustgi V, et al. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine. J Hepatol 2015;63:364-369.